Decade of IBioIC Support Boosts Scotland’s Bioeconomy with £35 Million of Innovation Investment

The Industrial Biotechnology Innovation Centre (IBioIC) has supported the growth of Scotland’s industrial biotechnology sector by helping it to attract £35 million of additional funding for research and development, according to new figures revealed to mark its tenth anniversary today (11 March).

Mark Bustard - CEO of IBioIC. Image Credit: IBioIC

IBioIC has supported more than 260 start-ups, small businesses, and established companies to bring bio-based processes and products to market, helping to create a thriving bioeconomy in Scotland. Building on £6.8 million of funding from the innovation centre, 215 projects have generated more than five times as much in additional investment from third-party sources.

Industrial biotechnology encompasses a range of techniques and processes, supporting the creation of more sustainable materials, consumer goods, and pharmaceuticals through the use of naturally sourced alternatives to petrochemicals. It also aims to maximise the use of by-products, and minimise waste, from existing industrial processes.

To commemorate its tenth year, the innovation centre is hosting a reception at the Scottish Parliament as part of Bioeconomy Week. and will also mark a decade of progress at its annual conference at Glasgow’s Technology and Innovation Centre on 13 and 14 March. Speakers include Teen Tech charity founder and TV personality Maggie Philbin, and the Scottish Government’s chief entrepreneurial adviser Mark Logan.

As a direct result of the innovation centre’s activity to date, the Scottish industrial biotechnology sector is exceeding growth expectations and is on track to achieve associated turnover of £1.2 billion by 2025, in line with the more ambitious target set out in an updated version of the National Plan for Industrial Biotechnology. The revised plan also sets a target of having 220 companies operating in the sector, supporting 4,000 jobs.

In January, Scotland’s First Minister announced that IBioIC had secured a long-term investment commitment from the Scottish Funding Council to continue the development of the bioeconomy and support Scotland’s transition to net zero.

Mark Bustard, chief executive of IBioIC, said: “Over the past decade, we have seen Scotland evolve into a leading innovation ecosystem – and we have the potential to become the go-to destination for scaling up bioeconomy businesses and manufacturing bio-based products and materials.

“IBioIC’s contribution has been central to the growth of the sector, and this is reflected in the projects we have supported, skills programmes delivered, and initiatives created, such as the Biotech Innovators accelerator for early-stage companies. Generating further impact will remain a key focus as we move forward. We will build on our efforts to support young businesses and entrepreneurs to develop more sustainable products through industrial biotechnology and help them secure the investment they need to take these ideas to a commercial stage.”

IBioIC’s membership network recently hit 200 companies, with LiYF Bioethanol taking it over the milestone figure. The Switzerland-headquartered start-up is exploring advanced second-generation bioethanol, produced from agricultural waste, that could reduce dependency on fossil fuels and contribute to net zero targets by unlocking the production of new biomolecules to replace fossil sources in the petrochemical industry.

It recently opened a facility in Ayrshire, with the ambition of establishing a pilot plant in Scotland for potential end users to validate the technology and trial the fuel.

The innovation centre’s network is designed to connect industry with Scotland’s academic expertise to support proof-of-concept projects. It also provides access to a range of support schemes for start-ups, skills programmes for developing talent, and access to bioprocess scale-up facilities – FlexBio and RapidBio. 

Hangama Wanner, founder and chief executive of LiYF Bioethanol, said: “Joining IBioIC’s network has provided us with opportunities to meet new partners from around the world that we likely wouldn’t have met otherwise, as well as access to valuable support from the innovation centre team. The next step in our journey involves expanding our global footprint, and Scotland’s thriving tech and start-up community really appealed to us as the next destination for driving this forward. We’re looking forward to developing our relationships with other IBioIC members and collaborating with academics and businesses that share our vision for expanding the scope of sustainable energy.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    IBioIC. (2024, March 12). Decade of IBioIC Support Boosts Scotland’s Bioeconomy with £35 Million of Innovation Investment. AZoLifeSciences. Retrieved on October 31, 2024 from https://www.azolifesciences.com/news/20240312/Decade-of-IBioIC-Support-Boosts-Scotlande28099s-Bioeconomy-with-c2a335-Million-of-Innovation-Investment.aspx.

  • MLA

    IBioIC. "Decade of IBioIC Support Boosts Scotland’s Bioeconomy with £35 Million of Innovation Investment". AZoLifeSciences. 31 October 2024. <https://www.azolifesciences.com/news/20240312/Decade-of-IBioIC-Support-Boosts-Scotlande28099s-Bioeconomy-with-c2a335-Million-of-Innovation-Investment.aspx>.

  • Chicago

    IBioIC. "Decade of IBioIC Support Boosts Scotland’s Bioeconomy with £35 Million of Innovation Investment". AZoLifeSciences. https://www.azolifesciences.com/news/20240312/Decade-of-IBioIC-Support-Boosts-Scotlande28099s-Bioeconomy-with-c2a335-Million-of-Innovation-Investment.aspx. (accessed October 31, 2024).

  • Harvard

    IBioIC. 2024. Decade of IBioIC Support Boosts Scotland’s Bioeconomy with £35 Million of Innovation Investment. AZoLifeSciences, viewed 31 October 2024, https://www.azolifesciences.com/news/20240312/Decade-of-IBioIC-Support-Boosts-Scotlande28099s-Bioeconomy-with-c2a335-Million-of-Innovation-Investment.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.